FBRX - Forte Biosciences, Inc. News

Forte Biosciences Files $500M Shelf Registration For Potential Issuance Of Common Stock, Preferred S

Forte Biosciences, Inc.$500,000,000Common StockPreferred StockDebt SecuritiesDepositary SharesWarran

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-sta

Forte Biosciences Q1 EPS $(1.24) Misses $(1.19) Estimate

Forte Biosciences (NASDAQ:FBRX) reported quarterly losses of $(1.24) per share which missed the anal

Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-sta

seekingalpha.com

Forte Biosciences: Stunning Bull Run Could Continue Thanks To Near-Term Data Readouts

Forte Biosciences has rebounded from near-liquidation, raising $150m this week and advancing FB102,

12 Health Care Stocks Moving In Thursday's Intraday Session

BlackBerry Posts Upbeat Q4 Results, Joins Constellation Brands, Marvell Technology And Other Big Sto

U.S. stocks fell, Dow Jones down 100+ points. BlackBerry (NYSE:BB) reported strong Q4 results and sa

Forte Biosciences Announces Pricing of $150 Million Public Offering

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical

Forte Biosciences Reveals Proposed Public Offering; No Size Disclosed

Forte Biosciences, Inc. (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimm

Forte Biosciences Announces Proposed Public Offering

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical

Forte Biosciences Target of Unusually High Options Trading (NASDAQ:FBRX)

Forte Biosciences, Inc. (NASDAQ: FBRX - Get Free Report) was the target of some unusual options trad

Forte Biosciences Q4 EPS $(1.45) Misses $(1.06) Estimate

Forte Biosciences (NASDAQ:FBRX) reported quarterly losses of $(1.45) per share which missed the anal

Forte Biosciences, Inc. Announces 2025 Results and Provides Update

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-sta

12 Health Care Stocks Moving In Thursday's After-Market Session

12 Health Care Stocks Moving In Wednesday's After-Market Session

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-sta

Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-sta

zacks.com

Forte Biosciences (FBRX) Upgraded to Buy: Here's What You Should Know

Forte Biosciences (FBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism abo

Forte Biosciences, Inc. to Present at Upcoming Investor Meetings

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-sta

Investors Purchase Large Volume of Forte Biosciences Call Options (NASDAQ:FBRX)

Forte Biosciences, Inc. (NASDAQ: FBRX - Get Free Report) was the recipient of unusually large option

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-sta

Forte Biosciences, Inc. (NASDAQ:FBRX) Given Average Rating of “Moderate Buy” by Brokerages

Forte Biosciences, Inc. (NASDAQ: FBRX - Get Free Report) has earned a consensus rating of "Moderate

Federated Hermes Inc. Buys New Shares in Forte Biosciences, Inc. $FBRX

Federated Hermes Inc. purchased a new position in shares of Forte Biosciences, Inc. (NASDAQ: FBRX) i

Forte Biosciences Target of Unusually High Options Trading (NASDAQ:FBRX)

Forte Biosciences, Inc. (NASDAQ: FBRX - Get Free Report) was the recipient of some unusual options t

Evercore ISI Group Initiates Coverage On Forte Biosciences with Outperform Rating, Announces Price T

Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on Forte Biosciences (NASDAQ:FB

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-sta

Chardan Capital Maintains Buy on Forte Biosciences, Maintains $61 Price Target

Chardan Capital analyst Daniil Gataulin maintains Forte Biosciences (NASDAQ:FBRX) with a Buy and

Forte Biosciences Q3 EPS $(0.99) Beats $(1.06) Estimate

Forte Biosciences (NASDAQ:FBRX) reported quarterly losses of $(0.99) per share which beat the analys

Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-sta

Forte Biosciences, Inc. $FBRX Stake Boosted by AlphaQuest LLC

AlphaQuest LLC grew its stake in shares of Forte Biosciences, Inc. (NASDAQ: FBRX) by 300.7% during t

Forte Biosciences Highlights FB102's Efficacy in Celiac Disease at Tampere Symposium, Underscoring H

Additional data continues to support highly differentiated profile for FB102 in celiac diseaseForte

Guggenheim Initiates Coverage On Forte Biosciences with Buy Rating, Announces Price Target of $75

Guggenheim analyst Yatin Suneja initiates coverage on Forte Biosciences (NASDAQ:FBRX) with a Buy

Chardan Capital Maintains Buy on Forte Biosciences, Maintains $61 Price Target

Chardan Capital analyst Daniil Gataulin maintains Forte Biosciences (NASDAQ:FBRX) with a Buy and

12 Health Care Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

12 Health Care Stocks Moving In Tuesday's After-Market Session

Forte Biosciences Announces Proposed Public Offering; No Size Or Amount Disclosed

Forte Biosciences, Inc. (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimm

Chardan Capital Maintains Buy on Forte Biosciences, Maintains $61 Price Target

Chardan Capital analyst Daniil Gataulin maintains Forte Biosciences (NASDAQ:FBRX) with a Buy and

12 Health Care Stocks Moving In Monday's Pre-Market Session

Forte Biosciences Reports Results in Celiac Disease Trial, Paving Way for Phase 2 in 2026

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical compa

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Monday's Pre-Market Session

Why Novavax Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

Forte Biosciences Q1 EPS $(1.37) Misses $(0.96) Estimate

Forte Biosciences (NASDAQ:FBRX) reported quarterly losses of $(1.37) per share which missed the anal

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

12 Health Care Stocks Moving In Monday's After-Market Session

12 Health Care Stocks Moving In Tuesday's Intraday Session

Why Forte Biosciences (FBRX) Stock Is Trading Lower

Forte Biosciences shares are trading lower by 13.6% Monday afternoon. The company announced plans fo

12 Health Care Stocks Moving In Wednesday's Pre-Market Session